Literature DB >> 22379999

Prediction of warfarin dose: why, when and how?

Niclas Eriksson1, Mia Wadelius.   

Abstract

Prediction models are the key to individualized drug therapy. Warfarin is a typical example of where pharmacogenetics could help the individual patient by modeling the dose, based on clinical factors and genetic variation in CYP2C9 and VKORC1. Clinical studies aiming to show whether pharmacogenetic warfarin dose predictions are superior to conventional initiation of warfarin are now underway. This review provides a broad view over the field of warfarin pharmacogenetics from basic knowledge about the drug, how it is monitored, factors affecting dose requirement, prediction models in general and different types of prediction models for warfarin dosing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22379999     DOI: 10.2217/pgs.11.184

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  25 in total

1.  Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.

Authors:  Wei Zhang; Yinan Zheng; Lifang Hou
Journal:  Curr Genet Med Rep       Date:  2013-09-01

2.  Functional Study of the Vitamin K Cycle Enzymes in Live Cells.

Authors:  J-K Tie; D W Stafford
Journal:  Methods Enzymol       Date:  2016-11-22       Impact factor: 1.600

3.  Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.

Authors:  Boxia Li; Ruisheng Liu; Chengqi Wang; Changan Ren; Shiming Zhang; Fan Zhang; Jianping Zhang; Shidong Liu; Yuhui Wei; Wenjing Liu; Bing Song; Xinan Wu
Journal:  Eur J Clin Pharmacol       Date:  2019-08-23       Impact factor: 2.953

4.  Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.

Authors:  Mennat-Allah Kamal El-Din; Marwa Salah Farhan; Randa Ibrahim El Shiha; Rania Mohammed Helmy El-Kaffas; Somaia Mohammed Mousa
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

5.  Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting.

Authors:  Vikas Srinivasan Sridhar; Philemon Leung; Nicole Seymour; Jeff Nagge
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

6.  Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Authors:  Nan Zhang; Ryan P Seguin; Kent L Kunze; Yan-Yan Zhang; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

7.  Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.

Authors:  J-K Tie; D-Y Jin; K Tie; D W Stafford
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

Review 8.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

9.  Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats.

Authors:  J John; M John; L Wu; C Hsiao; C V Abobo; D Liang
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

10.  Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.

Authors:  Alga S Ramos; Richard L Seip; Giselle Rivera-Miranda; Marcos E Felici-Giovanini; Rafael Garcia-Berdecia; Yirelia Alejandro-Cowan; Mohan Kocherla; Iadelisse Cruz; Juan F Feliu; Carmen L Cadilla; Jessica Y Renta; Krystyna Gorowski; Cunegundo Vergara; Gualberto Ruaño; Jorge Duconge
Journal:  Pharmacogenomics       Date:  2012-12       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.